Research Article
MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study
Table 1
Clinical characteristics of the study population.
| | Clinical parameter | Number of patients (%) | Statistical significance | | CAD, diabetes group | CAD, no-diabetes group |
| | Total number of patients | 35 (50) | 35 (50) | | | Age (years), mean ± SEM | 62.7 ± 1.5 | 60.1 ± 1.6 | NS | | Sex | | | | | Men | 27 (77.1) | 28 (80.0) | NS | | Women | 8 (22.9) | 7 (20.0) | NS | | Clinical characteristics | | | | | Arterial hypertension | 29 (82.8) | 28 (80.0) | NS | | Current tobacco use | 10 (28.5) | 15 (42.8) | NS | | History of myocardial infarction | 21 (60.0) | 13 (37.1) | NS | | History of PCI/CABG | 18 (51.4)/7 (20.0) | 10 (28.6)/3 (8.6) | NS | | History of stroke or TIA | 3 (8.5) | 2 (5.7) | NS | | Kidney insufficiency (GFR < 60 ml/min/m2), | 10 (28.5) | 5 (14.2) | NS | | Hypercholesterolemia | 35 (100) | 30 (85.7) | NS | | HbA1C, mean ± SD | 6.8 ± 3.0 | NA | NA | | Drug administration | | | | | Beta-blocker | 35 (100) | 32 (91.4) | NS | | Calcium channel blockers | 20 (57.1) | 22 (62.8) | NS | | ACE-I | 30 (85.7) | 31 (88.5) | NS | | ARB | 5 (14.2) | 10 (28.5) | NS | | Statins | 35 (100) | 35 (100) | NS | | Oral antidiabetic drugs | 30 (85) | NA | NA | | Insulin | 21 (65) | NA | NA | | HPR criteria | | | | | LTA (Amax > 20% | 2 (5.7) | 1 (2.8) | NS | | LTA (Amax > 15%) (highest quartile | 8 (22.8) | 4 (11.4) | NS | | MEA (AspiTEST > 30 AU) | 10 (28.6) | 9 (25.7) | NS | | TXB2 > 3.1 ng/ml | 15 (42.9) | 11 (31.4) | NS | | TXB2 > 5.8 ng/ml (highest quartile) | 9 (25.7) | 8 (22.9) | NS |
|
|
Notes. ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CABG: coronary artery bypass grafting; GFR: glomerular filtration rate; HbA1C: glycated hemoglobin A1C; LTA: light aggregometry; MEA: multielectrode aggregometry; NA: not analyzed; NS: not statistically significant; SD: standard deviation; PCI: percutaneous coronary intervention; TXB2: thromboxane B2; TIA: transient ischemic attack; range of values for LTA was 0–100%.
|
